IMA - Ikena Oncology, Inc.
5.84
-0.200 -3.425%
Share volume: 5,223
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.17%
PREVIOUS CLOSE
CHG
CHG%
$6.04
-0.20
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-08-2024 | 11-07-2024 | 03-06-2025 | 05-08-2025 | 07-24-2025 | 11-12-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 15.644 M | 15.140 M | 11.595 M | 12.175 M | 9.359 M | 8.441 M | 26.594 M | |
| Selling general and admin | 5.999 M | 5.308 M | 4.777 M | 7.595 M | 5.644 M | 4.416 M | 11.036 M | |
| Research and development | 9.645 M | 9.832 M | 6.818 M | 4.580 M | 3.715 M | 4.025 M | 15.558 M | |
| Total expenses | 18.226 M | 15.823 M | 12.407 M | 12.517 M | 10.794 M | 8.750 M | 26.594 M | |
| -13.18% | -21.59% | 0.89% | -13.77% | -18.94% | 203.93% | |||
| Operating income | -18.226 M | -15.823 M | -12.407 M | -12.517 M | -10.794 M | -8.750 M | -26.594 M | |
| Ebit | -18.233 M | -15.588 M | -11.995 M | -10.639 M | -10.009 M | -4.042 M | -24.757 M | |
| Pretax income | -16.119 M | -13.668 M | -10.224 M | -9.071 M | -8.591 M | -2.752 M | -24.853 M | |
| -15.21% | -25.20% | -11.28% | -5.29% | -67.97% | 803.09% | |||
| Income tax | 27.000 K | 62.000 K | 10.000 K | 53.000 K | 28.000 K | 15.000 K | -74.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -16.146 M | -13.730 M | -10.234 M | -9.124 M | -8.619 M | -2.767 M | -24.779 M | |
| 14.96% | 25.46% | 10.85% | 5.53% | 67.90% | -795.52% |